In this article, we deep dive into the 5 Resilient Stocks Beating Market Slump. For a deeper discussion and an extended list, please see 10 Resilient Stocks During Market Bloodbath.

5. Varonis Systems Inc. (NASDAQ:VRNS)

Varonis Systems climbed by 7.09 percent on Tuesday to finish at $35.03 apiece as investors loaded positions following reports that it is exploring a potential sale.

A report by Bloomberg said that Varonis Systems Inc. (NASDAQ:VRNS) is reviewing options after receiving takeover interest from financial buyers, namely Blackstone Inc., Thomas Bravo, and Vista Equity Partners.

It is said to be underway with the review of the options along with its financial advisers.

The sale report followed the rapidly growing demand for data solutions and cybersecurity products.

In other news, Varonis Systems Inc. (NASDAQ:VRNS) said last month that it integrated its security platform with Anthropic’s Claude AI through the Claude Compliance API, allowing security and governance teams to use Atlas to monitor AI usage across their organizations and alert on misuse.

Varonis Atlas ingests Claude Enterprise activity and administrative events, enabling security and governance teams to monitor conversational content, including chats, uploaded files, and projects; detect anomalies and misuse in real time; and maintain audit records to support internal governance and compliance assessments.

4. Viking Therapeutics Inc. (NASDAQ:VKTX)

Viking Therapeutics extended its winning streak to an 8th consecutive day on Tuesday, as investors gobbled up shares amid the growing appetite for the weight loss market, thanks to Medicare’s beginning of coverage of anti-obesity treatments.

Beginning July 1, 2026, Medicare, under its GLP-1 Bridge program, will start covering anti-obesity drugs such as Foundayo, Wegovy, and Zepbound for its members.

The news sparked interest among weight loss drug manufacturers, including Viking Therapeutics Inc. (NASDAQ:VKTX), which is underway with the development of its own VK2735 for obesity and type 2 diabetes.

Medicare aside, the stock’s rally can also be partly attributed to investor funds fleeing the AI sector towards other high-growth industries.

In other news, Viking Therapeutics Inc. (NASDAQ:VKTX) announced the appointment of Hubert Chen as its new chief medical officer.

Prior to joining the company, Chen served as chief research and development officer at Loyal Animal Health, where he led the first-ever FDA-negotiated effectiveness and safety requirements for longevity therapeutics. Previously, he was president and chief scientific officer at Forte Biosciences, CMO at Metacrine, and chief scientific and medical officer at Pfenex.

As Viking Therapeutics Inc.’s (NASDAQ:VKTX) new CMO, Chen is tasked to oversee clinical development, medical, and regulatory affairs.

3. Iovance Biotherapeutics Inc. (NASDAQ:IOVA)

Iovance Biotherapeutics saw its share prices increase by 9.36 percent to close at $4.44 apiece, as investors positioned portfolios ahead of the end of the second quarter, supported by a recent regulatory approval that opened the door for its expansion into a new international market.

It can be learned that earlier this month, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) secured the conditional approval of the Therapeutic Goods Administration (TGA) of Australia for Amtagvi—a tumor-derived autologous T-cell immunotherapy, for previously treated advanced (metastatic or unresectable) melanoma.

The company posted an optimistic outlook about Amtagvi’s business prospects in Australia, with the country having the highest rate of melanoma globally, with an estimated 17,000 new cases diagnosed each year and more than 1,500 deaths annually.

The go-signal marked Iovance Biotherapeutics Inc.’s (NASDAQ:IOVA) third marketing authorization for Amtagvi, after earlier securing the nod of the US and Canada for the same treatment.

“This approval … marks a significant step forward for Iovance in the country with the highest rate of melanoma globally,” Iovance Biotherapeutics Inc. (NASDAQ:IOVA) President and CEO Frederick Vogt said.

“We are in the process of authorizing our first Australian treatment center as we advance our expansion strategy for Amtagvi in additional markets with a high prevalence of advanced melanoma,” he added.

TGA granted approval based on safety and efficacy results from the global, multicenter C-144-01 trial investigating Amtagvi in patients with advanced melanoma previously treated with anti-PD-1 therapy and targeted therapy, if applicable.

2. Infleqtion Inc. (NYSE:INFQ)

Infleqtion saw its share prices surge by 12.32 percent on Tuesday to finish at $15.96 apiece as investors cheered the US government’s issuance of a new executive order to accelerate the development of quantum computing technologies.

In an EO published Monday, June 22, President Donald Trump ordered the government to supercharge US innovation in quantum technologies and strengthen the country’s national security in the area.

Among others, the order establishes a national effort to develop the first-ever quantum computer powerful enough to initiate the era of quantum-enabled scientific discovery and accelerate quantum capabilities for commercial applications. This includes evaluations of quantum computing system capabilities, an assessment of the resources necessary to build this science-enabling quantum computer, and development of specifications for such a system.

It also called on the Secretaries of Commerce, War, and Energy and the NASA Administrator to develop plans to deploy quantum-enabled sensors and networks in the next five years.

The EO followed the Department of Commerce’s $2 billion investment in seven quantum computing companies earlier this year.

Infleqtion Inc. (NYSE:INFQ) was among the government beneficiaries, having received $100 million in funding to develop the underlying engineering systems and integration requirements for large-scale neutral-atom-based quantum computers and architectures, including high-powered optical systems, novel readout, and error correction systems.

1. Quantinuum Inc. (NASDAQ:QNT)

Quantinuum saw its share prices increase by 13.46 percent on Tuesday to end at $77.46 apiece, as investors positioned their portfolios in quantum computing companies following an executive order that aims to accelerate the development of powerful computers.

Quantinuum Inc. (NASDAQ:QNT) rallied alongside its counterparts, namely Infleqtion Inc. (NYSE:INFQ) and D-Wave, following President Donald Trump’s issuance of a new EO to supercharge US innovation in quantum technologies and strengthen the country’s national security in the said area.

Among others, the order establishes a national effort to develop the first-ever quantum computer powerful enough to initiate the era of quantum-enabled scientific discovery and accelerate quantum capabilities for commercial applications.

This includes evaluations of quantum computing system capabilities, an assessment of the resources necessary to build this science-enabling quantum computer, and development of specifications for such a system.

It also called on the Secretaries of Commerce, War, and Energy and the NASA Administrator to develop plans to deploy quantum-enabled sensors and networks in the next five years.

The EO followed the Department of Commerce’s $2 billion investment in seven quantum computing companies earlier this year, including Quantinuum Inc. (NASDAQ:QNT), which received $100 million in funding to address critical technology and manufacturing bottlenecks for scaling of fault-tolerant trapped-ion-based quantum computers, such as low-loss integrated photonics, and reliable optical components at trapped-ion critical wavelengths.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.